Repeat PET/CT Imaging of Patients With Amyloid 124I-AT-01 to Measure Changes in Organ-specific Amyloid Load · Source last updated 2026-09-02
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
Measure
NUMBER
Unit
spearman correlation coefficient
Interval / dispersion
Not reported
Time frame
Baseline (assessed during previous study NCT03678259) and Repeat Assessment (Day 1 to Day 2 of current study)
What was measured
For AL, ATTR and all patients, we will correlate visual and quantitative changes in 124I- AT-01 uptake, from baseline, in the heart, liver and kidney with echocardiographic parameters (including left ventricular wall thickness (cm), intraventricular wall thickness (cm), and global logitudinal strain (%)) and serum biomarker levels (including NTproBNP, eGFR, creatinine, AST and ALT) assessed prior to imaging and from data recorded in the patients' medical record.
Analysis population: For serum biomarker (NT-proBNP), correlations are reported for both the absolute repeat values and the change from baseline. Because echocardiographic data was not available from the baseline imaging session, the correlation for echocardiographic parameters was performed using absolute values at repeat imaging.
Groups in this outcome
All Participants
Experimental: Patients will receive a single IV injection of 124I-AT-01 radiotracer and PET/CT imaging
In this repeat imaging study, patients previously enrolled in the AMY1001 study, in whom positive PET/CT imaging findings were observed will undergo repeat imaging to assess changes in radiotracer uptake in the liver, spleen, heart and kidneys.
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
Group
Source count
All Participants
19
Reported measurements
Cardiac SUVR change (%) vs NTproBNP change (%)
Values in spearman correlation coefficient · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Participants
0.57
Not reported
Not reported
Not reported
Not reported
Scaled cardiac SUVR change (%) vs NTproBNP change (%)
Values in spearman correlation coefficient · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Participants
0.62
Not reported
Not reported
Not reported
Not reported
Cardiac SUVR change vs NTproBNP change (pg/mL)
Values in spearman correlation coefficient · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Participants
0.43
Not reported
Not reported
Not reported
Not reported
correlation with cardiac SUVR - Left Ventricular (LV) wall thickness (cm) (Repat Imaging)
Values in spearman correlation coefficient · Interval/dispersion: Not reported
Correlation with renal SUVR - Urinary albumin/cre ratio (mg/g cre) (Repeat Imaging)
categories
measurements
group Id
OG000
value
0.06
title
Correlation with hepatic SUVR - Aspartate Aminotransferase (AST) (Repeat Imaging)
denoms
counts
group Id
OG000
value
19
units
Participants
description
For AL, ATTR and all patients, we will correlate visual and quantitative changes in 124I- AT-01 uptake, from baseline, in the heart, liver and kidney with echocardiographic parameters (including left ventricular wall thickness (cm), intraventricular wall thickness (cm), and global logitudinal strain (%)) and serum biomarker levels (including NTproBNP, eGFR, creatinine, AST and ALT) assessed prior to imaging and from data recorded in the patients' medical record.
groups
description
Experimental: Patients will receive a single IV injection of 124I-AT-01 radiotracer and PET/CT imaging
In this repeat imaging study, patients previously enrolled in the AMY1001 study, in whom positive PET/CT imaging findings were observed will undergo repeat imaging to assess changes in radiotracer uptake in the liver, spleen, heart and kidneys.
id
OG000
title
All Participants
param Type
NUMBER
population Description
For serum biomarker (NT-proBNP), correlations are reported for both the absolute repeat values and the change from baseline. Because echocardiographic data was not available from the baseline imaging session, the correlation for echocardiographic parameters was performed using absolute values at repeat imaging.
reporting Status
POSTED
time Frame
Baseline (assessed during previous study NCT03678259) and Repeat Assessment (Day 1 to Day 2 of current study)
Triangle